References
- Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative
disorders: summary of Society for Hematopathology
Workshop. Semin Diagn Pathol . 1997;14(1):8-14.
- Hussein K, Maecker-Kolhoff B, Klein C, Kreipe H.
Transplantations-assoziierte Lymphoproliferationen
[Transplant-associated lymphoproliferation]. Pathologe .
2011;32(2):152-158.
- Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant
lymphoproliferative disorders; in: Swerdlow SH, Campo E, Harris NL, et
al. (eds): WHO Classification of Tumors of Haematopoietic and Lymphoid
Tissues. Lyon (France): International Agency for Research on Cancer
(IARC). 2008; 343-348.
- Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B.
Incidence and consequences of post-transplantation lymphoproliferative
disorders. J Nephrol . 1997;10(3):136-145.
- Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW. Tumors and
transplantation: The 2003 Third Annual ASTS State-of-the-Art Winter
Symposium. Am J Transplant . 2003;3(12):1481-1487.
- Mynarek M, Schober T, Behrends U, Maecker-Kolhoff B. Posttransplant
lymphoproliferative disease after pediatric solid organ
transplantation. Clin Dev Immunol . 2013; 2013:814973.
- Narkewicz MR, Green M, Dunn S, et al. Decreasing incidence of
symptomatic Epstein-Barr virus disease and posttransplant
lymphoproliferative disorder in pediatric liver transplant recipients:
report of the studies of pediatric liver transplantation
experience. Liver Transpl . 2013;19(7):730-740.
- Allen U, Hébert D, Moore D, Dror Y, Wasfy S; Canadian PTLD Survey
Group–1998. Epstein-Barr virus-related post-transplant
lymphoproliferative disease in solid organ transplant recipients,
1988-97: a Canadian multi-centre experience. Pediatr
Transplant . 2001;5(3):198-203.
- Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant
lymphoproliferative disorder in solid organ transplant recipients -
BCSH and BTS Guidelines. Br J Haematol . 2010;149(5):675-692.
- Chinnock R, Webber SA, Dipchand AI, Brown RN, George JF; Pediatric
Heart Transplant Study. A 16-year multi-institutional study of the
role of age and EBV status on PTLD incidence among pediatric heart
transplant recipients. Am J Transplant . 2012;12(11):3061-3068.
- Opelz G, Daniel V, Naujokat C, Döhler B. Epidemiology of pretransplant
EBV and CMV serostatus in relation to posttransplant non-Hodgkin
lymphoma. Transplantation . 2009;88(8):962-967.
- Pinho-Apezzato ML, Tannuri U, Tannuri AC, et al. Multiple clinical
presentations of lymphoproliferative disorders in pediatric liver
transplant recipients: a single-center experience. Transplant
Proc . 2010;42(5):1763-1768.
- Elidemir O, Kancherla BS, Schecter MG, et al. Post-transplant
lymphoproliferative disease in pediatric lung transplant recipients:
recent advances in monitoring. Pediatr Transplant .
2009;13(5):606-610.
- Opelz G, Döhler B. Lymphomas after solid organ transplantation: a
collaborative transplant study report. Am J Transplant .
2004;4(2):222-230.
- Füreder A, Kropshofer G, Benesch M, et al. Characteristics,
management, and outcome of pediatric patients with post-transplant
lymphoproliferative disease-A 20 years’ experience from
Austria. Cancer Rep (Hoboken) . 2021;4(5):e1375.
- Gross TG, Savoldo B, Punnett A. Posttransplant Lymphoproliferative
Diseases. Pediatr Clin N Am . 2010; 57:481–503.
- Yanik EL, Shiels MS, Smith JM, et al. Contribution of solid organ
transplant recipients to the pediatric non-hodgkin lymphoma burden in
the United States. Cancer . 2017;123(23):4663-4671.
- Gross TG, Orjuela MA, Perkins, SL, et al. Low-Dose Chemotherapy and
Rituximab for Posttransplant Lymphoproliferative Disease (PTLD):A
Children’s Oncology Group Report. Am J Transplant.2012;12:3069–3075.
- Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for
Epstein-Barr virus-positive post-transplantation lymphoproliferative
disease in children after solid organ transplantation. J Clin
Oncol . 2005;23(27):6481-6488.
- Picarsic J, Jaffe R, Mazariegos G, et al. Post-Transplant Burkitt
Lymphoma Is a More Aggressive and Distinct Form of Post-Transplant
Lymphoproliferative Disorder. Cancer. 2011 Oct;117:4540–50.
- Baker A, Frauca Remacha E, Torres Canizales J, et al. Current
Practices on Diagnosis, Prevention and Treatment of Post-Transplant
Lymphoproliferative Disorder in Pediatric Patients after Solid Organ
Transplantation: Results of ERN TransplantChild Healthcare Working
Group Survey. Children (Basel) . 2021;8(8):661.
- González-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective
phase II trial of extended treatment with rituximab in patients with
B-cell post-transplant lymphoproliferative
disease. Haematologica . 2007;92(11):1489-1494.
- Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of
rituximab in B-cell post-transplantation lymphoproliferative
disorders: results of a prospective multicenter phase 2
study. Blood . 2006;107(8):3053-3057.
- Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T
cell immunotherapy for rituximab-refractory EBV-associated lymphoma
following transplantation. J Clin Invest . 2020;130(2):733-747.
- Giraldi E, Provenzi M, Fiocchi R, et al. Fludarabine,
cyclophosphamide, doxorubicin (FCD), and rituximab: a remission
induction therapy for aggressive pediatric post-transplant
lymphoproliferative disease (PTLD). Pediatr Blood Cancer .
2011;57(2):324-328.
- Giraldi E, Provenzi M, Conter V, et al. Risk-adapted Treatment for
Severe B-Lineage Posttransplant Lymphoproliferative Disease After
Solid Organ Transplantation in Children. Transplantation .
2016;100(2):437-445.
- Schober T, Framke T, Kreipe H, et al. Characteristics of early and
late PTLD development in pediatric solid organ transplant
recipients. Transplantation . 2013;95(1):240-246.
- Trappe RU, Dierickx D, Zimmermann H, et al. Response to Rituximab
Induction Is a Predictive Marker in B-Cell Post-Transplant
Lymphoproliferative Disorder and Allows Successful Stratification Into
Rituximab or R-CHOP Consolidation in an International, Prospective,
Multicenter Phase II Trial. J Clin Oncol . 2017;35(5):536-543.
- Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for
survival in adult solid organ transplant recipients with
post-transplantation lymphoproliferative disorders. J Clin
Oncol . 2005;23(30):7574-7582.
- Maecker-Kolhoff B, Beier R, Zimmermann M, et al. Response-adapted
sequential immuno-chemotherapy of post-transplant lymphoproliferative
disorders in pediatric solid organ transplant recipients: results from
the prospective Ped-PTLD 2005 trial. Blood, 2014; 124(21), 4468.
- Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96
chemotherapy in children with Stage III/IV B-cell non-Hodgkin
lymphoma: a Children’s Oncology Group report. Leukemia .
2013;27(5):1174-1177. doi:10.1038/leu.2012.255
- Prockop S, Mahadeo KM, Beitinjaneh A, et al. Multicenter, Open-Label,
Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic
Hematopoietic Cell Transplant Recipients with Epstein-Barr
Virus-Driven Post Transplant Lymphoproliferative Disease after Failure
of Rituximab or Rituximab and Chemotherapy
(ALLELE). Blood 2021; 138 (1): 301.
- Wang T, Feng M, Luo C, et al. Successful Treatment of Pediatric
Refractory Burkitt Lymphoma PTLD after Liver Transplantation using
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Cell
Transplant . 2021;30:963689721996649.
- Afify Z, Orjuela-Grimm M, Smith CM, et al. Burkitt lymphoma after
solid-organ transplant: Treatment and outcomes in the paediatric PTLD
collaborative. Br J Haematol . 2023;200(3):297-305.